Alistair James Mackett

Dr. Alistair James Mackett

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in touchREVIEWS in Neurology
Verified
Journal Article
Open access
PDF file
CCCaitríona L Cox
Caitríona L Cox
AMAlistair James Mackett
Alistair James Mackett
Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are

12 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LALedia Agley
Ledia Agley
JKJames Kilner
James Kilner
MHMark Hensley
Mark Hensley
AMAlistair James Mackett
Alistair James Mackett
Objective: To evaluate the feasibility, usability, and preliminary efficacy of the CUE1 wearable vibrotactile device in real-world, clinic-based older adults with Parkinson’s disease (PD). Methods: A single-arm feasibility study was conducted in 20 over 60-year-old participants with PD attending a routine movement disorders clinic. Par-ticipants used the CUE1 device daily for four weeks. Usability and acceptability were assessed through participant diaries. Motor outcomes were evaluated at two timepoint, baseline and after 4 weeks using MDS-UPDRS III and Timed Up and Go (TUG). Results: Sixteen participants completed the study. The CUE1 was well tolerated with minimal adverse events. Statistically significant improvements were observed in MDS-UPDRS III scores (mean change −4.5, p = 0.04) and TUG times (mean change −2.1s, p = 0.009). Im-provements were most pronounced in participants with greater baseline motor im-pairment. Conclusions: The CUE1 device demonstrated good feasibility, high usability, and promising motor improvements in older, real-world patients with PD who are often underrepresented in clinical trials. These findings support further evaluation of the CUE1 in larger, randomized controlled studies to confirm its clinical benefits and real-world applicability.